New Issue: Trillium prices $50.7 million public stock, preferreds at $19.50

By Devika Patel

Knoxville, Tenn., April 1 – Trillium Therapeutics Inc. said it priced a $50.7 million public offering of common stock and non-voting convertible preferred shares with a $4.45 million stock greenshoe. The deal was announced as a $50 million stock offering on March 11.

The company will sell 1,522,395 common shares and 1,077,605 preferreds at $19.50 per share or per preferred. The price per security is a 3.61% discount to the March 31 closing share price of $20.23.

Leerink Partners LLC and Cowen and Co., LLC are the bookrunning managers.

Settlement is expected April 7.

Proceeds will be used for product development, working capital and other general corporate purposes.

The immuno-oncology company is based in Toronto.

Issuer:	Trillium Therapeutics Inc.
Issue:	Common stock
Amount:	$50.7 million
Securities:	2.6 million
Price:	$19.50
Warrants:	No
Bookrunners:	Leerink Partners LLC and Cowen and Co., LLC
Co-manager:	Oppenheimer & Co. Inc.
Announcement date:	March 11
Pricing date:	April 1
Settlement date:	April 7
Stock symbol:	Nasdaq: TRIL
Stock price:	$20.23 at close March 31
Market capitalization:	$75.85 million
Stock
Amount:	$29,686,702.50
Greenshoe:	$4,453,000.5
Shares:	1,522,395
Preferreds
Amount:	$21,013,297.50
Shares:	1,077,605

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.